Hepatic Encephalopathy: Pharmacological Therapies Targeting Ammonia

Abstract

Hepatic encephalopathy (HE) is a major complication in patients with decompensated cirrhosis, leading to higher readmission rates causing a profound burden of disease and considerable health care costs. Because ammonia is thought to play a crucial role in the pathogenesis of HE, therapies directed at reducing ammonia levels are now being aggressively developed. Ammonia scavengers such as AST-120 (spherical carbon adsorbent), glycerol phenylbutyrate, sodium phenylacetate or sodium benzoate, and ornithine phenylacetate have been used to improve HE symptoms. A new approach, bowel cleansing with polyethylene glycol 3350, appears to be a promising therapy, with a recent study demonstrating a more rapid improvement in overt HE (at 24 hours after treatment) than lactulose. Extracorporeal devices, although now used primarily in research settings, have also been utilized in patients with refractory HE, but are not approved for clinical management.

Keywords

AST-120 - cirrhosis - glycerol phenylbutyrate - lactulose - molecular adsorbent recirculating system - ornithine phenylacetate - benzoate - polyethylene glycol

• References

• 1 Wong RJ, Gish RG, Ahmed A. Hepatic encephalopathy is associated with significantly increased mortality among patients awaiting liver transplantation. Liver Transpl 2014; 20 (12) 1454-1461
• 2 Blei AT, Córdoba J ; Practice Parameters Committee of the American College of Gastroenterology. Hepatic encephalopathy. Am J Gastroenterol 2001; 96 (7) 1968-1976
• 3 Vince AJ, Burridge SM. Ammonia production by intestinal bacteria: the effects of lactose, lactulose and glucose. J Med Microbiol 1980; 13 (2) 177-191
• 4 Floch MH, Katz J, Conn HO. Qualitative and quantitative relationships of the fecal flora in cirrhotic patients with portal systemic encephalopathy and following portacaval anastomosis. Gastroenterology 1970; 59 (1) 70-75
• 5 Wolpert E, Phillips SF, Summerskill WH. Ammonia production in the human colon. Effects of cleansing, neomycin and acetohydroxamic acid. N Engl J Med 1970; 283 (4) 159-164
• 6 Plauth M, Roske AE, Romaniuk P, Roth E, Ziebig R, Lochs H. Post-feeding hyperammonaemia in patients with transjugular intrahepatic portosystemic shunt and liver cirrhosis: role of small intestinal ammonia release and route of nutrient administration. Gut 2000; 46 (6) 849-855
• 7 Olde Damink SW, Jalan R, Redhead DN, Hayes PC, Deutz NE, Soeters PB. Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS. Hepatology 2002; 36 (5) 1163-1171
• 8 Romero-Gómez M, Ramos-Guerrero R, Grande L , et al. Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy. J Hepatol 2004; 41 (1) 49-54
• 9 Romero-Gómez M, Jover M, Del Campo JA , et al. Variations in the promoter region of the glutaminase gene and the development of hepatic encephalopathy in patients with cirrhosis: a cohort study. Ann Intern Med 2010; 153 (5) 281-288
• 10 Häussinger D, Kircheis G, Fischer R, Schliess F, vom Dahl S. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?. J Hepatol 2000; 32 (6) 1035-1038
• 11 Ghabril M, Zupanets IA, Vierling J , et al. Glycerol phenylbutyrate in patients with cirrhosis and episodic hepatic encephalopathy: a pilot study of safety and effect on venous ammonia concentration. Clin Pharm Drug Dev 2013; 2: 278-284
• 12 Rockey DC, Vierling JM, Mantry P , et al; HALT-HE Study Group. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology 2014; 59 (3) 1073-1083
• 13 Lee B, Rhead W, Diaz GA , et al. Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control. Mol Genet Metab 2010; 100 (3) 221-228
• 14 McGuire BM, Zupanets IA, Lowe ME , et al. Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis. Hepatology 2010; 51 (6) 2077-2085
• 15 Diaz GA, Krivitzky LS, Mokhtarani M , et al. Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate. Hepatology 2013; 57 (6) 2171-2179
• 16 Lichter-Konecki U, Diaz GA, Merritt II JL , et al. Ammonia control in children with urea cycle disorders (UCDs); phase 2 comparison of sodium phenylbutyrate and glycerol phenylbutyrate. Mol Genet Metab 2011; 103 (4) 323-329
• 17 Smith W, Diaz GA, Lichter-Konecki U , et al. Ammonia control in children ages 2 months through 5 years with urea cycle disorders: comparison of sodium phenylbutyrate and glycerol phenylbutyrate. J Pediatr 2013; 162 (6) 1228-1234 , 1234.e1
• 18 Jalan R, Wright G, Davies NA, Hodges SJ. L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy. Med Hypotheses 2007; 69 (5) 1064-1069
• 19 Ventura-Cots M, Arranz JA, Simón-Talero M , et al. Safety of ornithine phenylacetate in cirrhotic decompensated patients: an open-label, dose-escalating, single-cohort study. J Clin Gastroenterol 2013; 47 (10) 881-887
• 20 Córdoba J, Ventura-Cots M. Drug-induced removal of nitrogen derivatives in urine: a new concept whose time has come. Hepatology 2014; 59 (3) 764-766
• 21 Shoji T, Wada A, Inoue K , et al. Prospective randomized study evaluating the efficacy of the spherical adsorptive carbon AST-120 in chronic kidney disease patients with moderate decrease in renal function. Nephron Clin Pract 2007; 105 (3) c99-c107
• 22 Schulman G, Agarwal R, Acharya M, Berl T, Blumenthal S, Kopyt N. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis 2006; 47 (4) 565-577
• 23 Sanaka T, Sugino N, Teraoka S, Ota K. Therapeutic effects of oral sorbent in undialyzed uremia. Am J Kidney Dis 1988; 12 (2) 97-103
• 24 Owada A, Nakao M, Koike J, Ujiie K, Tomita K, Shiigai T. Effects of oral adsorbent AST-120 on the progression of chronic renal failure: a randomized controlled study. Kidney Int Suppl 1997; 63: S188-S190
• 25 Shen B, Pardi DS, Bennett AE , et al. The efficacy and tolerability of AST-120 (spherical carbon adsorbent) in active pouchitis. Am J Gastroenterol 2009; 104 (6) 1468-1474
• 26 Hiraishi M. The effect of oral adsorbent on surgically induced hepatic failure. Jpn J Surg 1987; 17 (6) 517-527
• 27 Pockros P, Hassanein T, Vierling J , et al. Phase 2, multicenter, randomized study of ast-120 (spherical carbon adsorbent) vs. lactulose in the treatment of low-grade hepatic encephalopathy (HE). J Hepatol 2009; 50: S43-S44
• 28 Bosoi CR, Parent-Robitaille C, Anderson K, Tremblay M, Rose CF. AST-120 (spherical carbon adsorbent) lowers ammonia levels and attenuates brain edema in bile duct-ligated rats. Hepatology 2011; 53 (6) 1995-2002
• 29 Kundra A, Jain A, Banga A, Bajaj G, Kar P. Evaluation of plasma ammonia levels in patients with acute liver failure and chronic liver disease and its correlation with the severity of hepatic encephalopathy and clinical features of raised intracranial tension. Clin Biochem 2005; 38 (8) 696-699
• 30 Palm K, Luthman K, Ros J, Grasjo J, Artursson P. Effect of molecular charge on intestinal epithelial drug transport: pH-dependent transport of cationic drugs. J Pharmacol Exp Ther 1999; 291 (2) 435-443
• 31 Bajaj JS, Sheikh MY, Chojkier M , et al. AST-120 (spherical carbon adsorbent) in covert hepatic encephalopathy: results of the astute trial. J Hepatol 2013; 58 (5): S84
• 32 Hassanein TI, Tofteng F, Brown Jr RS , et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007; 46 (6) 1853-1862
• 33 Hill K, Hu KQ, Cottrell A, Teichman S, Hillebrand DJ. Charcoal-based hemodiabsorption liver support for episodic type C hepatic encephalopathy. Am J Gastroenterol 2003; 98 (12) 2763-2770
• 34 Tsipotis E, Shuja A, Jaber BL. Albumin dialysis for liver failure: a systematic review. Adv Chronic Kidney Dis 2015; 22 (5) 382-390
• 35 Rahimi RS, Singal AG, Cuthbert JA, Rockey DC. Lactulose vs polyethylene glycol 3350–electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial. JAMA Intern Med 2014; 174 (11) 1727-1733
• 36 Hammer HF, Santa Ana CA, Schiller LR, Fordtran JS. Studies of osmotic diarrhea induced in normal subjects by ingestion of polyethylene glycol and lactulose. J Clin Invest 1989; 84 (4) 1056-1062
• 37 Rahimi RS, Cuthbert JA, Rockey DC. Lactulose vs polyethylene glycol for treatment of hepatic encephalopathy: reply. JAMA Intern Med 2015; 175 (5) 868-869